EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori ‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial

Jing Wen Liang iD, Si Xiong, Ye Gui Jia, Dan Xiao, Shi Yun Tan, Ji Wang Cao, Jun Sun, Xia Tian, Shu Yu Li, Rui Hong Chen, Gui Zhen Ruan, Jian Guang Xiong und 17 weitere

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16679 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Jing Wen Liang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Sulfonamides, Helicobacter pylori, Pyrroles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Helicobacter pylori infection is linked to various gastrointestinal conditions, such as chronic active gastritis, peptic ulcers, and gastric cancer. Traditional treatment options encounter difficulties due to antibiotic resistance and adverse effects. Therefore, the aim of this study was to explore the effectiveness of a new treatment plan that combines vonoprazan (VPZ), amoxicillin, and bismuth for the eradication of H. pylori .

Methods

A total of 600 patients infected with H. pylori were recruited for this multicenter randomized controlled trial. Patients treated for H. pylori elimination were randomly assigned at a 1:1 ratio to receive 14 days of vonoprazan‐based triple therapy (vonoprazan + amoxicillin + bismuth, group A) or standard quadruple therapy (esomeprazole + clarithromycin + amoxicillin + bismuth, group B). Compliance and adverse effects were tracked through daily medication and side effect records. All patients underwent a 13C/14C‐urea breath test 4 weeks after treatment completion.

Results

Intention‐to‐treat (ITT) and per‐protocol (PP) analyses revealed no substantial differences in H. pylori eradication rates between groups A and B (ITT: 83.7% vs 83.2%; PP: 90.9% vs 89.7%). However, significant differences were observed in the assessment of side effects (13.7% vs 28.6%, P < 0.001). Specifically, group A had significantly fewer “bitter mouths” than group B did (3.7% vs 16.2%, P < 0.001).

Conclusion

Triple therapy comprising vonoprazan (20 mg), amoxicillin (750 mg), and bismuth potassium citrate (220 mg) achieved a PP eradication rate ≥90%, paralleling standard quadruple therapy, and had fewer adverse events and lower costs (¥306.8 vs ¥645.8) for treatment‐naive patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsSulfonamidesHelicobacter pyloriPyrrolesDrug Therapy, CombinationAmoxicillinBismuthHumansMaleFemaleMiddle AgedProspective StudiesTreatment OutcomeAnti-Bacterial AgentsClarithromycinAgedProton Pump InhibitorsBreath TestsAdult

Stichwörter der Autor:innen

GastroenterologyHelicobacter pylori: treatment and antimicrobial resistanceamoxicillinclarithromycinvonoprazan

Substanzen

Sulfonamides1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesAmoxicillinBismuthAnti-Bacterial AgentsClarithromycinProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Gastroenterology, Wuhan City Sixth Hospital, Wuhan, China.
  • Department of Gastroenterology, Hubei General Hospital, Wuhan, China.
  • Department of Gastroenterology, Wuhan City Third Hospital, Wuhan, China.
  • Department of Gastroenterology, Zhongshan Hospital of Hubei Province, Wuhan, China.
  • Department of Gastroenterology, Xiantao First People's Hospital Affiliated to Yangtze University, Xiantao, China.

ORCID-Profile: Jing Wen Liang, Bin Cheng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liang, J. W., Xiong, S., Jia, Y. G., Xiao, D., Tan, S. Y., Cao, J. W., Sun, J., Tian, X., Li, S. Y., Chen, R. H., Ruan, G. Z., Xiong, J. G., Wang, X. M., Xu, S. P., Qi, L. P., Liu, Y. H., Zhao, Y. C., Bai, S. Y., Chen, W., …, & Cheng, B. (2024). Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori ‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16679

Vancouver

Liang JW, Xiong S, Jia YG, Xiao D, Tan SY, Cao JW, et al. Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori ‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16679

BibTeX
@article{Liang2024,
  author = {Liang, Jing Wen and Xiong, Si and Jia, Ye Gui and Xiao, Dan and Tan, Shi Yun and Cao, Ji Wang and Sun, Jun and Tian, Xia and Li, Shu Yu and Chen, Rui Hong and Ruan, Gui Zhen and Xiong, Jian Guang and Wang, Xiao Ming and Xu, San Ping and Qi, Li Ping and Liu, Yun Hua and Zhao, Yu Chong and Bai, Shu Ya and Chen, Wei and Cao, Meng Die and Peng, Wang and Li, Yan Ling and Yang, Yi Lei and Chen, Shi Ru and Cui, Hao Chen and Liu, Lu Yao and Aruna and Zhou, Yi and Cheng, Bin},
  title = {Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori ‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16679}
}
Kostenlos starten →